Investigating the Spectrum of Normoglycemia: Time in Glycemic Ranges and Their Association With Metabolic Outcomes in
Anastasia Godneva1,2, Moshe Phillip3,4, Eran Segal1,5
1Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.
Objective:
To characterize the distribution of time in tight and broader glycemic ranges in adults without diabetes and to examine cross-sectional and longitudinal associations with metabolic health.
Research Design And Methods:
We analyzed continuous glucose monitoring data from 8,687 adults (40-70 years, 54% women) in the Human Phenotype Project, each contributing 1,149 ± 279 glucose readings from FreeStyle Libre Pro sensors. Age- and sex-adjusted correlations linked time-in-range metrics with 45 clinical phenotypes encompassing adiposity, vascular, and liver markers, sleep indices, and nutrition. Cox models tested associations of time above glycemic thresholds with incident metabolic disease over 2.6 ± 1.3 years.
Results:
Participants spent a median 93.0% (interquartile range [IQR] 91.8-98.2) of continuous glucose monitor time within 70-140 mg/dL and 95.2% (IQR 95.1-99.8) within 70-180 mg/dL. Time below 140 mg/dL and 180 mg/dL was 97.7% (IQR 97.6-97.8) and 99.9% (IQR 99.9-99.9), respectively. Less time at <140 mg/dL correlated with higher waist circumference, visceral fat, triglycerides, blood pressure, serum ALT, and liver attenuation, and with lower HDL cholesterol and mean nocturnal oxygen saturation. Associations weakened using the <180 mg/dL threshold. Less time at <180 mg/dL and <140 mg/dL was associated with higher risk of incident metabolic disease (hazard ratio 1.21 [95% CI 1.15-1.26] and 1.34 [95% CI 1.26-1.42], respectively).
Conclusions:
We provide population references for time spent in different glycemic ranges by adults without diabetes. Although our study is observational and not designed to establish causality, our findings suggest that even within normoglycemic ranges, less time at <140 mg/dL is associated with unfavorable health parameters and higher incident metabolic disease risk.
More Related Videos
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
06:59Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
Related Concept Videos
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes Mellitus: Type 2 and Gestational
Hypoglycemia and Glucagon
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
